Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

SKBI, PROT, MNTA - Stock Alerts! from - Skystar Bio-Pharmaceutical, Proteonomix, Momenta Pharmaceuticals

|Includes: Momenta Pharmaceuticals, Inc. (MNTA)







  Proteonomix, Inc. (OTCPK:PROT)

PROT, a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced recently that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. ("XGen"), a Nevis Island limited liability company.

"Proteonomix has made great strides recently," stated Mr. Cohen, "and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships."

PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of PROT that has recently opened its retail web site,, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (NYSE:CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is PROT's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. PROT intends to create and dedicate a subsidiary to each of its technologies. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.

To learn more about PROT visit:


  Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI)

SKBI, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, announces update regarding its Hubei acquisition.

SKBI completed acquisition of a modern, GMP-certified veterinary medicine facility in Hubei Province on August 11, 2010. SKBI estimates the Hubei facility, located in Jingzhou, Hubei Province, will contribute about $4 million to $6 million in revenue in a normalized full fiscal year. SKBI estimates that the Hubei facility will be completely finished and ramped up by the end of the 2010 calendar year. Blended gross margins for the products anticipated to be made at the Hubei facility are expected to be in the range of 40%-50%.

In other company news, Weibing Lu, CEO, & R. Scott Cramer, Director and U.S. Representative of SKBI, will visit NASDAQ MarketSite in Times Square and preside over the closing bell.

Where:  NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio

When:  Tuesday, September 14, 2010 at 3:50 p.m. - 4:00 p.m. ET

SKBI engages in the research, development, production, marketing, and sale of veterinary healthcare and medical care products in the People's Republic of China. SKBI's products include veterinary medicine for poultry and livestock; micro-organism products; bio-pharmaceutical veterinary vaccines; and feed additives. SKBI offers its products through distributors and directly to customers. SKBI is headquartered in Xian, the People's Republic of China.

To learn more about SKBI visit:


  Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA)

MNTA, a biotechnology company specializing in the characterization and engineering of complex drugs, announced recently that on September 7, 2010 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,790,466, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin that involve identifying chain sequence information.

"This patent provides further validation of our innovative approach to the characterization and ongoing quality control of enoxaparin," said Craig Wheeler, President and CEO of MNTA. "Issuance of this patent strengthens our expanding portfolio of patents and pending applications related to methods and tools for the identification and analysis of enoxaparin, and provides intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox."

MNTA, a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). MNTA applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. MNTA's product candidates include M-Enoxaparin, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate. MNTA has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. MNTA was founded in 2001 and is based in Cambridge, Massachusetts.

To learn more about MNTA visit:



Signup for FREE Daily Stock Alerts From 


Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT)